A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Regorafenib (Primary)
- Indications Colon cancer
- Focus Therapeutic Use
- Acronyms ARGO
- 05 Dec 2017 Planned End Date changed from 1 Jan 2025 to 1 Oct 2019.
- 05 Dec 2017 Planned primary completion date changed from 1 Nov 2023 to 1 Oct 2019.
- 05 Dec 2017 Status changed from recruiting to active, no longer recruiting.